3F8
3F8| 단클론 항체 | |
|---|---|
| 유형 | ? |
| 출처 | 마우스 |
| 대상 | GD2 |
| 임상자료 | |
| 경로: 행정 | 정맥의 |
| ATC 코드 |
|
| 식별자 | |
| CAS 번호 | |
| 켐스파이더 |
|
| | |
3F8은 GD2에 결합되는 뮤린 IgG3[1] 단클론 항체다.[2]
그것은 신경블라스토마 검출과 치료에 사용되어 왔다.[3]영상 신경블라스토종의 경우 방사성동위원소 요오드-124와 요오드-131 중 하나로 라벨을 표시한다.[4][5]
참고 항목
참조
- ^ Kushner BH, Cheung NK (May 1989). "GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma". Blood. 73 (7): 1936–41. doi:10.1182/blood.V73.7.1936.1936. PMID 2653466. Archived from the original on 2020-05-26. Retrieved 2008-02-20.
- ^ "Sloan-Kettering - Neuroblastoma: 3F8 Monoclonal Antibody Therapy Q & A". Retrieved 2008-02-19.
- ^ Weinstein JL, Katzenstein HM, Cohn SL (1 June 2003). "Advances in the diagnosis and treatment of neuroblastoma". The Oncologist. 8 (3): 278–92. doi:10.1634/theoncologist.8-3-278. PMID 12773750. S2CID 20705441.
- ^ Yeh SD, Larson SM, Burch L, Kushner BH, Laquaglia M, Finn R, Cheung NK (May 1991). "Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities". Journal of Nuclear Medicine. 32 (5): 769–76. PMID 1902508.
- ^ Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, Divgi C (January 2007). "Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma". Health Physics. 92 (1): 33–9. doi:10.1097/01.HP.0000231583.32904.6c. PMID 17164597. S2CID 25792466.